(PRWEB) June 15, 2005
SCIREX Corporation today announced that Cornelia Kamp has been appointed Executive Officer, Office of the President, Clinical Site Operations, a newly created position that centralizes the operational monitoring, accountability, and financial management of SCIREXÂs Clinical Research Centers. Additionally, Kamp will collaborate on strategy, direction and budgeting for clinical operations and will be closely involved in the recruitment and professional development of the companyÂs site managers and clinic supervisors. Ms. Kamp will report directly to SCIREX Chief Executive Officer Jim Utterback and will be a member of the companyÂs Senior Management Committee.
Kamp joins SCIREX after 15 years at the University Of Rochester Medical Center where she held several positions of increasing responsibility, most recently as Director, Research Operations, Department of Neurology, Clinical Trials Coordination Center. She received her B.S. degree in Biological Sciences/German Language and Literature from the State University of New York at Binghamton, and her M.B.A. in Finance and Operations Management from the William E. Simon Graduate School of Business Administration, University of Rochester, New York. She is also an ACRP-certified Clinical Research Coordinator and the author or co-author of several research papers published in Neurology, JAMA, Clinical Neuropharmacology, Archives of Neurology, Annals of Neurology, Movement Disorders, Brain Pathology, and other professional journals.
SCIREX Corporation is a leader in the delivery of Phase I-IV drug development services to the global pharmaceutical and biotechnology industries. SCIREXÂs clinical trial management capabilities include drug development planning, protocol design, submission services, regulatory affairs consulting, investigator and patient recruitment, data management, statistics, medical writing and offers an array of technology solutions including IVRS, EDC and SIMS(TM) (Study Information Management System). SCIREXÂs experience portfolio includes more than 1,000 clinical trials involving well over 100,000 patients, evaluating new treatments for pain and inflammation, neurological and psychiatric disorders, infectious diseases and gastrointestinal and cardiovascular indications. SCIREX is a wholly-owned subsidiary of Omnicom Group, Inc.
For more information contact Blythe Vito, SCIREX Corporate Marketing at (215) 907-1330 x1054, or visit http://www.scirex.com.